Female Pelvic Med Reconstr Surg. 2020 Nov;26(11):682-687. doi: 10.1097/SPV.0000000000000650.
This study aimed to determine the effect of tamsulosin on postoperative urinary retention in female patients after pelvic reconstructive surgery.
Data were obtained from a retrospective, matched cohort of female patients who were admitted after pelvic reconstructive surgery at a single academic institution. Patients who received tamsulosin were compared with those who did not at a 1:4 ratio, matched by surgical procedure. Patients were excluded if they were discharged on the day of surgery or if an intraoperative complication necessitated prolonged postoperative bladder drainage. Information on demographics, preoperative diagnoses, prolapse stage, preoperative voiding dysfunction, urodynamic findings, intraoperative details, postoperative complications, and voiding outcomes up to 6 weeks after surgery was gathered. The primary outcome was postoperative urinary retention, defined by failure of an active voiding trial.
Patients underwent surgery between January 2016 and March 2018. We identified 35 patients who received tamsulosin and matched to 140 controls. Patients in the tamsulosin group were younger; groups were otherwise similar. Patients who received tamsulosin after surgery were less likely to develop postoperative urinary retention (2.9% vs 24.3%, P = 0.004). After controlling for confounders, multivariable logistic regression identified tamsulosin use as the only independent predictor of postoperative urinary retention with a significant protective effect (odds ratio, 0.09; 95% confidence interval, 0.01-0.67; P = 0.03).
Prophylactic tamsulosin use may be effective in preventing postoperative urinary retention in female patients undergoing pelvic reconstructive surgery.
本研究旨在确定坦索罗辛对女性盆腔重建术后患者术后尿潴留的影响。
资料来源于单家学术机构收治的女性盆腔重建术后患者的回顾性、匹配队列研究。以 1:4 的比例,按手术程序将接受坦索罗辛治疗的患者与未接受坦索罗辛治疗的患者进行匹配。如果患者在手术当天出院,或术中并发症需要延长术后膀胱引流,则排除患者。收集了人口统计学、术前诊断、脱垂分期、术前排尿功能障碍、尿动力学检查结果、手术细节、术后并发症以及术后 6 周内排尿结果等信息。主要结局是术后尿潴留,定义为主动排尿试验失败。
患者于 2016 年 1 月至 2018 年 3 月期间接受手术。共识别出 35 例接受坦索罗辛治疗的患者,并与 140 例对照患者相匹配。坦索罗辛组患者更年轻,两组在其他方面相似。接受坦索罗辛治疗的患者发生术后尿潴留的可能性较低(2.9% vs. 24.3%,P=0.004)。在控制混杂因素后,多变量逻辑回归发现坦索罗辛的使用是术后尿潴留的唯一独立预测因素,具有显著的保护作用(比值比,0.09;95%置信区间,0.01-0.67;P=0.03)。
在接受盆腔重建手术的女性患者中,预防性使用坦索罗辛可能有效预防术后尿潴留。